Tretinoin - Scotia

Drug Profile

Tretinoin - Scotia

Latest Information Update: 22 Jan 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 22 Jan 2002 Discontinued-Clinical for Acne in United Kingdom (Unknown route)
  • 07 Feb 2001 Clinical data have been added to the adverse events and Skin Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top